BioXcel Therapeutics, Inc. 8-K

What Happened
BioXcel Therapeutics, Inc. announced its financial results for the three months and year ended December 31, 2025 and provided a corporate business update via a press release dated March 27, 2026. The company filed a Current Report on Form 8-K (Item 2.02) to furnish that press release, which is included as Exhibit 99.1 and is incorporated by reference into the filing.

Key Details

• Filing date: March 27, 2026 (Form 8-K).
• Reporting period: three months and year ended December 31, 2025 (Q4 2025 and full-year 2025 results).
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Interactive XBRL cover page data also included (Exhibit 104).

Why It Matters
This filing signals that BioXcel has released its latest earnings and a business update; investors should review the press release for the specific financial figures (revenue, net income or loss, cash position) and any operational or strategic news that could affect valuation. Because the 8-K itself furnishes the press release rather than restating financial line items in full, shareholders and analysts will need to read Exhibit 99.1 to assess quarterly results, year-over-year performance, and any guidance or material developments disclosed.